VINCRISTINE Side Effects

7014448-2 | Jaundice Cholestatic
on Sep 17, 2010 Male patient from UNITED KINGDOM , 60 years of age, was diagnosed with glioma and was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: jaundice cholestatic. Vincristine dosage: . Patient was hospitalized.

7004837-4 | Pneumococcal Infection
Patient was taking Vincristine (View Usage). Patient had the following side effects: pneumococcal infection on Sep 20, 2010 from UNITED KINGDOM Additional patient health information: Female patient , child 1 years of age, . Vincristine dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6988446-9 | Pneumococcal Infection
Adverse event was reported on Sep 03, 2010 by a Female patient taking Vincristine (View Usage) (Dosage: ) . Location: UNITED KINGDOM , child 1 years of age, After Vincristine was administered, patient had the following side effects: pneumococcal infection. During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

6942987-9 | Skin Necrosis
on Aug 17, 2010 Male patient from NETHERLANDS , weighting 165.3 lb, was diagnosed with non-hodgkin's lymphoma and was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: skin necrosis. Vincristine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HYDROCHLORIDE (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), PEGFILGRASTIM (View Pegfilgrastim Review and Pegfilgrastim Label ), INSULIN ASPART (View Insulin Aspart Review and Insulin Aspart Label ), INSULIN DETEMIR (View Insulin Detemir Review and Insulin Detemir Label ), FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ).


6930209-4 | Progressive Multifocal Leukoencephalopathy, Pyrexia
on Aug 13, 2010 Male patient from UNITED KINGDOM , 71 years of age, was diagnosed with waldenstrom's macroglobulinaemia and was treated with Vincristine (View Usage). Patient had the following side effects: progressive multifocal leukoencephalopathy, pyrexia. Vincristine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

6929775-4 | Confusional State, Nuclear Magnetic Resonance Imaging Brain Abnormal, Reversible Posterior Leukoencephalopathy Syndrome, Vision Blurred, Visual Acuity Reduced
Patient was taking Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: confusional state, nuclear magnetic resonance imaging brain abnormal, reversible posterior leukoencephalopathy syndrome, vision blurred, visual acuity reduced on Aug 03, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 60 years of age, . Vincristine dosage: . During the same period patient was treated with DOXORUBICIN HYDROCHLORIDE (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6760594-8 | Gastroenteritis, Neutropenia
Adverse event was reported on May 28, 2010 by a Male patient taking Vincristine (View Usage) (Dosage: 2 Mg Cyclic) was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii recurrent and. Location: ITALY , 69 years of age, Patient experienced the following unwanted or unexpected effects: gastroenteritis (What is gastroenteritis?), neutropenia. During the same period patient was treated with ADRIBLASTINA (90 Mg Cyclic) (View Adriblastina Review and Adriblastina Label ), CYCLOPHOSPHAMIDE (1350 Mg Cyclic) (View Cyclophosphamide Review and Cyclophosphamide Label ), URBASON (80 Mg Cyclical) (View Urbason Review and Urbason Label ), PREDNISONE (75 Mg Cyclical) (View Prednisone Review and Prednisone Label ), ALLOPURINOL (300 Mg) (View Allopurinol Review and Allopurinol Label ), ZOFRAN (8 Mg) (View Zofran Review and Zofran Label ), SELEPARINA (1.4 Ml) (View Seleparina Review and Seleparina Label ), LEVOXACIN (500 Mg) (View Levoxacin Review and Levoxacin Label ). Patient was hospitalized.

6759695-X | Mucormycosis
on May 24, 2010 Female patient from TURKEY , 63 years of age, was treated with Vincristine (View Usage). Patient had the following side effects: mucormycosis. Vincristine dosage: . During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ).

6756741-4 | Ileus Paralytic
on May 24, 2010 Male patient from FRANCE , 39 years of age, was treated with Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: ileus paralytic. Vincristine dosage: . During the same period patient was treated with LOPINAVIR AND RITONAVIR (400mg/100mg) (View Lopinavir And Ritonavir Review and Lopinavir And Ritonavir Label ), ABACAVIR SULFATE/LAMIVUDINE (View Abacavir Sulfate/lamivudine Review and Abacavir Sulfate/lamivudine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

6729954-5 | Chest Pain, Dyspnoea, Flushing, Muscular Weakness
Patient was taking Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: chest pain (What is chest pain?), dyspnoea, flushing, muscular weakness on Apr 29, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 58 years of age, weighting 145.5 lb, was diagnosed with non-hodgkin's lymphoma and. Vincristine dosage: 1200 Mg,3 Week, Intravenous. During the same period patient was treated with (MABTHERA) (630 Mg, 3 Week, Intravenous) (View (mabthera) Review and (mabthera) Label ), CYCLOPHOSPHAMIDE (120 Mg, 3 Week, Intravenous) (View Cyclophosphamide Review and Cyclophosphamide Label ), DRISTAN (View Dristan Review and Dristan Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ).

6724093-1 | Ecthyma, Pseudomonas Infection
Adverse event was reported on May 03, 2010 by a Male patient taking Vincristine (View Usage) (Dosage: ) was diagnosed with astrocytoma and. Location: NETHERLANDS , 37 years of age, Patient had the following side effects: ecthyma, pseudomonas infection. During the same period patient was treated with LOMUSTINE (View Lomustine Review and Lomustine Label ), PROCARBAZINE (View Procarbazine Review and Procarbazine Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), LEVETIRACETAM (View Levetiracetam Review and Levetiracetam Label ), VALPROIC ACID (View Valproic Acid Review and Valproic Acid Label ), CLOBAZAM (View Clobazam Review and Clobazam Label ). Patient was hospitalized.

6700295-5 | Gastroenteritis, Neutropenia
on Apr 20, 2010 Male patient from ITALY , 69 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii recurrent and was treated with Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: gastroenteritis (What is gastroenteritis?), neutropenia. Vincristine dosage: 2 Mg Cyclic. During the same period patient was treated with ADRIBLASTINA (90 Mg Cyclic) (View Adriblastina Review and Adriblastina Label ), CYCLOPHOSPHAMIDE (1350 Mg Cyclic) (View Cyclophosphamide Review and Cyclophosphamide Label ), URBASON (80 Mg Cyclical) (View Urbason Review and Urbason Label ), PREDNISONE (75 Mg Cyclical) (View Prednisone Review and Prednisone Label ), ALLOPURINOL (300 Mg) (View Allopurinol Review and Allopurinol Label ), ZOFRAN (8 Mg) (View Zofran Review and Zofran Label ), SELEPARINA (1.4 Ml) (View Seleparina Review and Seleparina Label ), LEVOXACIN (500 Mg) (View Levoxacin Review and Levoxacin Label ). Patient was hospitalized.

6688199-8 | Gastroenteritis, Neutropenia
on Apr 09, 2010 Male patient from ITALY , 69 years of age, was diagnosed with follicle centre lymphoma, follicular grade i, ii, iii recurrent and was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: gastroenteritis (What is gastroenteritis?), neutropenia. Vincristine dosage: 2 Mg Cyclic. During the same period patient was treated with ADRIBLASTINA (90 Mg Cyclic) (View Adriblastina Review and Adriblastina Label ), CYCLOPHOSPHAMIDE (1350 Mg Cyclic) (View Cyclophosphamide Review and Cyclophosphamide Label ), URBASON (80 Mg Cyclical) (View Urbason Review and Urbason Label ), PREDNISONE TAB (75 Mg Cyclical) (View Prednisone Tab Review and Prednisone Tab Label ), ALLOPURINOL (300 Mg) (View Allopurinol Review and Allopurinol Label ), ZOFRAN (8 Mg) (View Zofran Review and Zofran Label ), SELEPARINA (1.4 Ml) (View Seleparina Review and Seleparina Label ), LEVOXACIN (500 Mg) (View Levoxacin Review and Levoxacin Label ). Patient was hospitalized.

6665127-2 | Tumour Lysis Syndrome
Patient was taking Vincristine (View Usage). Patient had the following side effects: tumour lysis syndrome on Mar 29, 2010 from KOREA, REPUBLIC OF Additional patient health information: Male patient , 33 years of age, . Vincristine dosage: . During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

6649136-5 | Anal Fissure, Constipation, Dermatitis Bullous, Impaired Healing, Rash, Skin Exfoliation
Adverse event was reported on Mar 15, 2010 by a Female patient taking Vincristine (View Usage) (Dosage: ) was diagnosed with rhabdomyosarcoma and. Location: FRANCE , weighting 35.94 lb, After Vincristine was administered, patient had the following side effects: anal fissure, constipation (What is constipation?), dermatitis bullous, impaired healing, rash (What is rash?), skin exfoliation. During the same period patient was treated with BEVACIZUMAB (View Bevacizumab Review and Bevacizumab Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

6644586-5 | Chills, Hypotension, Pyrexia, Sepsis
on Mar 18, 2010 Male patient from UNITED STATES , weighting 55.12 lb, was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: chills, hypotension, pyrexia, sepsis (What is sepsis?). Vincristine dosage: 3.6 Mg. During the same period patient was treated with DEXAMETHASONE (55 Mg) (View Dexamethasone Review and Dexamethasone Label ), MERCAPTOPURINE (3600 Mg) (View Mercaptopurine Review and Mercaptopurine Label ), METHOTREXATE (172 Mg) (View Methotrexate Review and Methotrexate Label ). Patient was hospitalized.

6609383-5 | Acute Respiratory Distress Syndrome, Neutropenia, Pneumonia, Pulmonary Haemorrhage, Sepsis, Zygomycosis
on Feb 22, 2010 Male patient from AUSTRIA , 15 years of age, was diagnosed with acute lymphocytic leukaemia and was treated with Vincristine (View Usage). Patient had the following side effects: acute respiratory distress syndrome, neutropenia, pneumonia (What is pneumonia?), pulmonary haemorrhage, sepsis (What is sepsis?), zygomycosis. Vincristine dosage: . During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PEGASPARGASE (Unit Dose: 1000 U/m2) (View Pegaspargase Review and Pegaspargase Label ).

6609382-3 | Acute Respiratory Distress Syndrome, Pancytopenia, Zygomycosis
Patient was taking Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: acute respiratory distress syndrome, pancytopenia, zygomycosis on Feb 22, 2010 from AUSTRIA Additional patient health information: Female patient , 15 years of age, was diagnosed with acute lymphocytic leukaemia and. Vincristine dosage: . During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ASPARAGINASE (Unit Dose: 1000 U/m2) (View Asparaginase Review and Asparaginase Label ).

6566924-4 | Colitis Ulcerative, Gastrointestinal Inflammation, Hepatotoxicity, Intestinal Haemorrhage, Pulmonary Mycosis
Adverse event was reported on Jan 25, 2010 by a Female patient taking Vincristine (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia and. Location: ITALY , 20 years of age, Patient experienced the following unwanted or unexpected effects: colitis ulcerative, gastrointestinal inflammation, hepatotoxicity, intestinal haemorrhage, pulmonary mycosis. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), IDARUBICIN HYDROCHLORIDE (View Idarubicin Hydrochloride Review and Idarubicin Hydrochloride Label ), METHYLPREDNISOLONE SODIUM SUCCINATE (View Methylprednisolone Sodium Succinate Review and Methylprednisolone Sodium Succinate Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), ASPARAGINASE (View Asparaginase Review and Asparaginase Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

6551207-9 | Chest Pain, Dyspnoea, Flushing, Muscular Weakness
on Jan 05, 2010 Female patient from UNITED KINGDOM , 58 years of age, weighting 145.5 lb, was diagnosed with non-hodgkin's lymphoma and was treated with Vincristine (View Usage). Patient had the following side effects: chest pain (What is chest pain?), dyspnoea, flushing, muscular weakness. Vincristine dosage: 1200 Mg, 3 Weeks, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (120 Mg, 3 Week, Intravenous) (View Cyclophosphamide Review and Cyclophosphamide Label ), (MABTHERA) (630 Mg, 3 Week, Intravenous) (View (mabthera) Review and (mabthera) Label ), (PARACETAMOL) (View (paracetamol) Review and (paracetamol) Label ), DRISTAN (View Dristan Review and Dristan Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6540567-0 | Neuropathy Peripheral
on Jan 04, 2010 Female patient from TURKEY , 17 years of age, was diagnosed with hodgkin's disease (What is hodgkin's disease?) and was treated with Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: neuropathy peripheral. Vincristine dosage: 2 Mg, Intravenous. During the same period patient was treated with ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), BLEOMYCIN SULFATE (View Bleomycin Sulfate Review and Bleomycin Sulfate Label ), DACARBAZINE (View Dacarbazine Review and Dacarbazine Label ).

6538723-0 | Aplasia, Blood Culture Positive, Enterococcal Infection, Staphylococcal Infection
Patient was taking Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: aplasia, blood culture positive, enterococcal infection, staphylococcal infection (What is staphylococcal infection?) on Jan 14, 2010 from FRANCE Additional patient health information: Male patient , child 11 years of age, weighting 17.64 lb, was diagnosed with lymphocytic leukaemia and. Vincristine dosage: 400 Mcg, 1 Week, Intravenous. During the same period patient was treated with LANVIS (View Lanvis Review and Lanvis Label ), CERUBIDINE (View Cerubidine Review and Cerubidine Label ), (ENDOXAN /00021101/) (View (endoxan /00021101/) Review and (endoxan /00021101/) Label ), CYTARABINE (21 Mg, 4 Week, Intravenous) (View Cytarabine Review and Cytarabine Label ), (KIDROLASE) (View (kidrolase) Review and (kidrolase) Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6536996-1 | Aplasia, Blood Culture Positive, Enterococcal Infection, Staphylococcal Infection
Adverse event was reported on Dec 17, 2009 by a Male patient taking Vincristine (View Usage) (Dosage: 400 Mcg, 1 Week, Intravenous) was diagnosed with lymphocytic leukaemia and. Location: FRANCE , child 11 years of age, weighting 17.64 lb, Patient had the following side effects: aplasia, blood culture positive, enterococcal infection, staphylococcal infection (What is staphylococcal infection?). During the same period patient was treated with (LANVIS) (20 Mg, Oral) (View (lanvis) Review and (lanvis) Label ), CERUBIDINE (8500 Mcg, 1 Week) (View Cerubidine Review and Cerubidine Label ), (ENDOXAN /00021101/) (140 Mg, Intravenous) (View (endoxan /00021101/) Review and (endoxan /00021101/) Label ), CYTARABINE (21 Mg, 4 Week, Intravenous; 15 Mg (1 Year) Intrathecal) (View Cytarabine Review and Cytarabine Label ), (KIDROLASE) (678 Iu, Intravenous) (View (kidrolase) Review and (kidrolase) Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), BRICANYL (View Bricanyl Review and Bricanyl Label ). Patient was hospitalized.

6536994-8 | Progressive Multifocal Leukoencephalopathy
on Dec 18, 2009 Male patient from UNITED KINGDOM , 70 years of age, was diagnosed with chronic lymphocytic leukaemia and was treated with Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: progressive multifocal leukoencephalopathy. Vincristine dosage: . During the same period patient was treated with PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), (RITUXIMAB) (View (rituximab) Review and (rituximab) Label ).

6535803-0 | Alanine Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased
on Dec 17, 2009 Male patient from UNITED KINGDOM , child 2 years of age, was diagnosed with fungal infection (What is fungal infection?) and was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased. Vincristine dosage: . During the same period patient was treated with VFEND (View Vfend Review and Vfend Label ), (CO TRIMOXAZOLE) (View (co-trimoxazole) Review and (co-trimoxazole) Label ), (POTASSIUM CHLORIDE) (View (potassium Chloride) Review and (potassium Chloride) Label ).

6528507-1 | Aplasia, Pallor, Staphylococcal Sepsis, Tachycardia
Patient was taking Vincristine (View Usage). Patient had the following side effects: aplasia, pallor, staphylococcal sepsis, tachycardia on Dec 09, 2009 from FRANCE Additional patient health information: Male patient , child 3 years of age, was diagnosed with neuroblastoma (What is neuroblastoma?) and. Vincristine dosage: Intravenous. During the same period patient was treated with (ENDOXAN /00021101/) (Intravenous) (View (endoxan /00021101/) Review and (endoxan /00021101/) Label ), DOXORUBICIN HCL (Intravenous) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), SECTRAL (View Sectral Review and Sectral Label ), NICARDIPINE HCL (View Nicardipine Hcl Review and Nicardipine Hcl Label ), (TRIATEC /00885601/) (View (triatec /00885601/) Review and (triatec /00885601/) Label ), KAYEXALATE (View Kayexalate Review and Kayexalate Label ), SODIUM BICARBONATE (View Sodium Bicarbonate Review and Sodium Bicarbonate Label ), (ONEALFA) (View (onealfa) Review and (onealfa) Label ). Patient was hospitalized.

6527485-9 | Convulsion, Leukoencephalopathy
Adverse event was reported on Dec 22, 2009 by a Male patient taking Vincristine (View Usage) (Dosage: ) was diagnosed with acute lymphocytic leukaemia and. Location: AUSTRALIA , child 6 years of age, After Vincristine was administered, patient had the following side effects: convulsion, leukoencephalopathy. During the same period patient was treated with CYTARABINE (View Cytarabine Review and Cytarabine Label ), ASPARAGINASE (View Asparaginase Review and Asparaginase Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), MERCAPTOPURINE (View Mercaptopurine Review and Mercaptopurine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6521988-9 | Agranulocytosis
on Dec 24, 2009 Female patient from FRANCE , 82 years of age, was diagnosed with lymphoma (What is lymphoma?) and was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: agranulocytosis. Vincristine dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), PEGFILGRASTIM (View Pegfilgrastim Review and Pegfilgrastim Label ). Patient was hospitalized.

6517033-1 | Alanine Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Yellow Skin
on Dec 15, 2009 Male patient from UNITED KINGDOM , child 2 years of age, was diagnosed with fungal infection (What is fungal infection?) and was treated with Vincristine (View Usage). Patient had the following side effects: alanine aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, yellow skin. Vincristine dosage: . During the same period patient was treated with VORICONAZOLE (View Voriconazole Review and Voriconazole Label ).

6479986-X | Aplasia, Blood Culture Positive, Enterococcal Infection, Staphylococcal Infection
Patient was taking Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: aplasia, blood culture positive, enterococcal infection, staphylococcal infection (What is staphylococcal infection?) on Nov 17, 2009 from FRANCE Additional patient health information: Male patient , child 11 years of age, weighting 17.64 lb, was diagnosed with lymphocytic leukaemia and. Vincristine dosage: 400 Mcg ( 1 Week ), Intravenous. During the same period patient was treated with (LANVIS) (20 Mg, Oral) (View (lanvis) Review and (lanvis) Label ), (CERUBIDINE) (8500 Mcg ( 1 Week )) (View (cerubidine) Review and (cerubidine) Label ), (ENDOXAN /00021101/) (140 Mg, Intravenous) (View (endoxan /00021101/) Review and (endoxan /00021101/) Label ), CYTARABINE (21 Mg ( 4 Week), Intravenous; 15 Mg (1 Year), Intrathecal) (View Cytarabine Review and Cytarabine Label ), (KIDROLASE) (678 Iu, Intravenous) (View (kidrolase) Review and (kidrolase) Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), (DEXAMETIASONE) (View (dexametiasone) Review and (dexametiasone) Label ). Patient was hospitalized.

6458764-1 | Blood Creatine Phosphokinase Increased, Myalgia
Adverse event was reported on Nov 12, 2009 by a Female patient taking Vincristine (View Usage) (Dosage: ) was diagnosed with malignant hydatidiform mole and. Location: UNITED KINGDOM , 38 years of age, weighting 64.00 lb, Patient experienced the following unwanted or unexpected effects: blood creatine phosphokinase increased, myalgia. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6447786-2 | Blood Creatine Phosphokinase Increased, Myalgia
on Nov 12, 2009 Female patient from UNITED KINGDOM , 38 years of age, weighting 141.1 lb, was diagnosed with malignant hydatidiform mole and was treated with Vincristine (View Usage). Patient had the following side effects: blood creatine phosphokinase increased, myalgia. Vincristine dosage: .

6446343-1 | Diffuse Large B-cell Lymphoma Recurrent, Stem Cell Transplant
on Nov 06, 2009 Male patient from UNITED STATES , 74 years of age, was diagnosed with diffuse large b-cell lymphoma and was treated with Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: diffuse large b-cell lymphoma recurrent, stem cell transplant. Vincristine dosage: 5 Cycles. During the same period patient was treated with CYCLOPHOSPHAMIDE (5 Cycles) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (5 Ctckes) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISONE (5 Cycles) (View Prednisone Review and Prednisone Label ), RITUXIMAB (5 Cycles) (View Rituximab Review and Rituximab Label ). Patient was hospitalized.

6446339-X | Mass, Spleen Disorder
Patient was taking Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: mass, spleen disorder on Nov 06, 2009 from UNITED STATES Additional patient health information: Male patient , 67 years of age, was diagnosed with diffuse large b-cell lymphoma and. Vincristine dosage: 6 Cycles. During the same period patient was treated with CYCLOPHOSPHAMIDE (6 Cycles) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (6 Cycle) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISONE (6 Cycle) (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6443854-X | Neurotoxicity, Reversible Posterior Leukoencephalopathy Syndrome
Adverse event was reported on Nov 04, 2009 by a Female patient taking Vincristine (View Usage) (Dosage: Intravenous) was diagnosed with acute myeloid leukaemia and. Location: TURKEY , 20 years of age, Patient had the following side effects: neurotoxicity, reversible posterior leukoencephalopathy syndrome. During the same period patient was treated with METHOTREXATE (Intravenous) (View Methotrexate Review and Methotrexate Label ), (ASPARAGINASE) (Intravenous) (View (asparaginase) Review and (asparaginase) Label ), (DOXORUBICIN) (View (doxorubicin) Review and (doxorubicin) Label ).

6443511-X | Acute Myeloid Leukaemia, Ewing's Sarcoma Metastatic
on Nov 04, 2009 Female patient from UNITED STATES , 22 years of age, was diagnosed with ewing's sarcoma, ewing's sarcoma metastatic and was treated with Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: acute myeloid leukaemia, ewing's sarcoma metastatic. Vincristine dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ).

6427338-0 | Guillain-barre Syndrome, Leukocytosis
on Oct 28, 2009 Male patient from SWITZERLAND , weighting 178.6 lb, was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: guillain-barre syndrome (What is guillain-barre syndrome?), leukocytosis. Vincristine dosage: . During the same period patient was treated with PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), PEGFILGRASTIM (View Pegfilgrastim Review and Pegfilgrastim Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6424424-6 | Aplasia
Patient was taking Vincristine (View Usage). Patient had the following side effects: aplasia on Oct 19, 2009 from FRANCE Additional patient health information: Male patient , child 11 years of age, weighting 17.64 lb, was diagnosed with lymphocytic leukaemia and. Vincristine dosage: 400 Mcg, 1 Week, Intravenous. During the same period patient was treated with (LANVIS) (20 Mg, Oral) (View (lanvis) Review and (lanvis) Label ), CERUBIDINE (8500 Mcg, 1 Week) (View Cerubidine Review and Cerubidine Label ), (ENDOXAN /00021101/) (140 Mcg, Intravenous) (View (endoxan /00021101/) Review and (endoxan /00021101/) Label ), CYTARABINE (See Image) (View Cytarabine Review and Cytarabine Label ), (KIDROLASE) (678 Iu Intravenous) (View (kidrolase) Review and (kidrolase) Label ), METHYLPREDNISOLONE 4MG TAB (View Methylprednisolone 4mg Tab Review and Methylprednisolone 4mg Tab Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6407895-0 | Neuropathy Peripheral
Adverse event was reported on Oct 09, 2009 by a Male patient taking Vincristine (View Usage) (Dosage: ) was diagnosed with t-cell lymphoma stage iv and. Location: CANADA , child 12 years of age, After Vincristine was administered, patient had the following side effects: neuropathy peripheral. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), (ASPARAGINASE) (View (asparaginase) Review and (asparaginase) Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), (DAUNOMYCIN /00128201/) (View (daunomycin /00128201/) Review and (daunomycin /00128201/) Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ).

6403212-0 | Altered State Of Consciousness, Coagulopathy, Dialysis, Disease Recurrence, Hepatic Encephalopathy, Hepatic Failure, Hepatitis B, Hypoalbuminaemia
on Oct 02, 2009 Female patient from TAIWAN, PROVINCE OF CHINA , 52 years of age, was diagnosed with diffuse large b-cell lymphoma and was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: altered state of consciousness, coagulopathy, dialysis (What is dialysis?), disease recurrence, hepatic encephalopathy, hepatic failure, hepatitis b (What is hepatitis b?), hypoalbuminaemia. Vincristine dosage: 6 Cycles. During the same period patient was treated with PREDNISOLONE (6 Cycles) (View Prednisolone Review and Prednisolone Label ), RITUXIMAB (RITUXIMAB) (6 Cycles) (View Rituximab (rituximab) Review and Rituximab (rituximab) Label ), CYCLOPHOSPHAMIDE (6 Cycles) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (6 Cycles) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ). Patient was hospitalized.

6402914-X | Cough, Eye Swelling, Oxygen Saturation Decreased, Pallor, Rash, Urticaria, Vomiting
on Oct 14, 2009 Male patient from UNITED STATES , child 3 years of age, weighting 36.38 lb, was diagnosed with brain neoplasm and was treated with Vincristine (View Usage). Patient had the following side effects: cough, eye swelling, oxygen saturation decreased, pallor, rash (What is rash?), urticaria, vomiting. Vincristine dosage: 1mg Once Iv.

6398875-2 | B-cell Lymphoma Recurrent, Bacterial Sepsis, Metastases To Bone Marrow, Metastases To Lymph Nodes, Neuropathy Peripheral, Procedural Complication
Patient was taking Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: b-cell lymphoma recurrent, bacterial sepsis, metastases to bone marrow, metastases to lymph nodes, neuropathy peripheral, procedural complication on Sep 30, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 55 years of age, was diagnosed with diffuse large b-cell lymphoma refractory and. Vincristine dosage: 1.4 Mg/m2, Intravenous. During the same period patient was treated with (CALCIUM FOLINATE) (View (calcium Folinate) Review and (calcium Folinate) Label ), EPIRUBICIN (View Epirubicin Review and Epirubicin Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), MITOXANTRONE HYDROCHLORIDE (View Mitoxantrone Hydrochloride Review and Mitoxantrone Hydrochloride Label ), DEXAMETHASONE 0.5MG TAB (View Dexamethasone 0.5mg Tab Review and Dexamethasone 0.5mg Tab Label ), IDARUBICIN HCL (View Idarubicin Hcl Review and Idarubicin Hcl Label ).

6398388-8 | Hepatitis B Virus Test
Adverse event was reported on Oct 05, 2009 by a Female patient taking Vincristine (View Usage) (Dosage: ) . Location: TAIWAN, PROVINCE OF CHINA , 52 years of age, Patient experienced the following unwanted or unexpected effects: hepatitis b virus test. During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6388999-8 | Blood Lactate Dehydrogenase Increased, Epstein-barr Virus Antigen Positive, Interstitial Lung Disease, Lymphadenopathy, Pneumocystis Jiroveci Pneumonia
on Sep 24, 2009 Male patient from UNITED STATES , 85 years of age, was diagnosed with diffuse large b-cell lymphoma and was treated with Vincristine (View Usage). Patient had the following side effects: blood lactate dehydrogenase increased, epstein-barr virus antigen positive, interstitial lung disease, lymphadenopathy, pneumocystis jiroveci pneumonia. Vincristine dosage: Every 21 Days,. During the same period patient was treated with DOXORUBICIN HCL (Every 21 Days,) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (Every 21 Days,) (View Cyclophosphamide Review and Cyclophosphamide Label ), PREDNISONE (Every 21 Days,) (View Prednisone Review and Prednisone Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

6360627-7 | Ataxia, Central Nervous System Lesion, Cerebellar Syndrome, Dysarthria, Head Titubation, Nystagmus, Progressive Multifocal Leukoencephalopathy
on Sep 03, 2009 Female patient from UNITED STATES , 59 years of age, was diagnosed with non-hodgkin's lymphoma and was treated with Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: ataxia (What is ataxia?), central nervous system lesion, cerebellar syndrome, dysarthria, head titubation, nystagmus, progressive multifocal leukoencephalopathy. Vincristine dosage: . During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), MITOXANTRONE (View Mitoxantrone Review and Mitoxantrone Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), RITUXIMAB (RITUXIMAB) (View Rituximab (rituximab) Review and Rituximab (rituximab) Label ).

6360315-7 | Pancytopenia
Patient was taking Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: pancytopenia on Sep 11, 2009 from TAIWAN, PROVINCE OF CHINA Additional patient health information: Male patient , 75 years of age, was diagnosed with acute leukaemia, lymphoma (What is lymphoma?) and. Vincristine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), EPIRUBICIN (View Epirubicin Review and Epirubicin Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), COLCHICINE (View Colchicine Review and Colchicine Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), BETAMETHASONE (View Betamethasone Review and Betamethasone Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ).

6360306-6 | Arachnoiditis, Neurocryptococcosis
Adverse event was reported on Sep 10, 2009 by a Female patient taking Vincristine (View Usage) (Dosage: Unit: 1.5mg/m2 At Day 1) was diagnosed with glioma and. Location: FRANCE , child 6 years of age, Patient had the following side effects: arachnoiditis, neurocryptococcosis. During the same period patient was treated with CARBOPLATIN (Unit: 150mg/m2 At Day 1) (View Carboplatin Review and Carboplatin Label ), TEMOZOLOMIDE (Unit: 150mg From Day 2 To Day 6) (View Temozolomide Review and Temozolomide Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

6355676-9 | Coagulopathy, Hepatic Failure, Hepatitis B, Hypoalbuminaemia
on Sep 03, 2009 Female patient from , 52 years of age, was diagnosed with diffuse large b-cell lymphoma and was treated with Vincristine (View Usage). After Vincristine was administered, patient had the following side effects: coagulopathy, hepatic failure, hepatitis b (What is hepatitis b?), hypoalbuminaemia. Vincristine dosage: . During the same period patient was treated with RITUXIMAB (View Rituximab Review and Rituximab Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ).

6342754-3 | Bone Marrow Disorder, Neuropathy Peripheral, Sepsis
on Aug 24, 2009 Female patient from UNITED KINGDOM , 55 years of age, was diagnosed with diffuse large b-cell lymphoma and was treated with Vincristine (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow disorder, neuropathy peripheral, sepsis (What is sepsis?). Vincristine dosage: . During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ), RITUXIMAB (View Rituximab Review and Rituximab Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6335375-X | Arachnoiditis, Neurocryptococcosis
Patient was taking Vincristine (View Usage). Patient had the following side effects: arachnoiditis, neurocryptococcosis on Aug 24, 2009 from FRANCE Additional patient health information: Female patient , child 6 years of age, was diagnosed with glioma and. Vincristine dosage: Unit: 1.5mg/m2 At Day 1. During the same period patient was treated with CARBOPLATIN (Unit: 150mg/m2 At Day 1) (View Carboplatin Review and Carboplatin Label ), TEMOZOLOMIDE (Unit: 150mg From Day 2 To Day 6) (View Temozolomide Review and Temozolomide Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).